Compare Johnson & Johnson (JNJ) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Western Alliance Bancorporation — how do they compare? Johnson & Johnson trades at $260.84 (market cap $626.09B), while Western Alliance Bancorporation trades at $82.11 (market cap $8.89B). The key difference: Johnson & Johnson is far larger — about 70.4× Western Alliance Bancorporation's market cap, and Johnson & Johnson is trading nearer its 52-week high, Western Alliance Bancorporation nearer its low. Which is the better fit depends on your goals.
| JNJ | WAL | |
|---|---|---|
Market Cap | $626.09B | $8.89B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $96.08 |
52-Week Low | $172.78 | $66.70 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Western Alliance Bancorporation (WAL) trades at $81.64, up 1.44% today, with a neutral technical signal and bullish analyst consensus. The stock shows strong fundamentals, including a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's top bank by Forbes in 2026.
The outlook for WAL is positive, with a consensus price target of $93.86 implying 15% upside, driven by revenue growth and profitability. Risks include negative operating cash flow and high interest expenses. Institutional sentiment is mixed, with some firms reducing stakes, but overall analyst ratings remain heavily bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
